PMID- 26893584
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160219
LR  - 20200930
IS  - 1179-271X (Print)
IS  - 1179-271X (Electronic)
IS  - 1179-271X (Linking)
VI  - 7
DP  - 2016
TI  - Mapping of Multiple Sclerosis Walking Scale (MSWS-12) to five-dimension EuroQol 
      (EQ-5D) health outcomes: an independent validation in a randomized control 
      cohort.
PG  - 13-8
LID - 10.2147/PROM.S96956 [doi]
AB  - BACKGROUND: Mapping of patient-reported outcomes to the five-dimension EuroQol 
      (EQ-5D) health index is increasingly being used for understanding the 
      relationship of outcomes to health states and for predicting utilities that have 
      application in economic evaluations. The 12-item Multiple Sclerosis Walking Scale 
      (MSWS-12) is a patient-reported outcome that assesses the impact of walking 
      impairment in people with MS. An equation for mapping the MSWS-12 to the EQ-5D 
      was previously developed and validated using a North American Research Committee 
      on MS (NARCOMS) registry cohort. MATERIALS AND METHODS: This analysis retested 
      the validity of the equation mapping the MSWS-12 to the three-level EQ-5D 
      (EQ-5D-3L) by using an independent cohort of patients with MS enrolled in a 
      randomized controlled trial. Mapping was evaluated at two separate time points 
      (baseline and week 4) during the clinical trial. The mapping equation's 
      performance was subsequently assessed with mean absolute error (MAE) and 
      root-mean-square error (RMSE) by comparing equation-based estimates to values 
      elicited in the trial using the actual EQ-5D-3L questionnaire. RESULTS: The 
      mapping equation predicted EQ-5D-3L values in this external cohort with 
      reasonable precision at both time points (MAE 0.116 and RMSE 0.155 at baseline; 
      MAE 0.105 and RMSE 0.138 at week 4), and was similar to that reported in the 
      original NARCOMS cohort (MAE 0.109 and RMSE 0.145). Also as observed in the 
      original NARCOMS cohort, the mapping equation performed best in patients with 
      EQ-5D-3L values between 0.50 and 0.75, and poorly in patients with values <0.50. 
      CONCLUSION: The mapping equation performed similarly in this external cohort as 
      in the original derivation cohort, including a poorer performance in MS patients 
      with more severe health-state severity.
FAU - Sidovar, Matthew F
AU  - Sidovar MF
AD  - Clinical Development and Medical Affairs, Acorda Therapeutics, Ardsley, NY.
FAU - Limone, Brendan L
AU  - Limone BL
AD  - Department of Pharmacy Practice, University of Connecticut School of Pharmacy, 
      Storrs, CT, USA.
FAU - Coleman, Craig I
AU  - Coleman CI
AD  - Department of Pharmacy Practice, University of Connecticut School of Pharmacy, 
      Storrs, CT, USA.
LA  - eng
PT  - Journal Article
DEP - 20160203
PL  - New Zealand
TA  - Patient Relat Outcome Meas
JT  - Patient related outcome measures
JID - 101551170
PMC - PMC4745957
OTO - NOTNLM
OT  - EQ-5D-3L
OT  - MSWS-12
OT  - health status index
OT  - health-related quality of life
OT  - mapping
EDAT- 2016/02/20 06:00
MHDA- 2016/02/20 06:01
PMCR- 2016/02/03
CRDT- 2016/02/20 06:00
PHST- 2016/02/20 06:00 [entrez]
PHST- 2016/02/20 06:00 [pubmed]
PHST- 2016/02/20 06:01 [medline]
PHST- 2016/02/03 00:00 [pmc-release]
AID - prom-7-013 [pii]
AID - 10.2147/PROM.S96956 [doi]
PST - epublish
SO  - Patient Relat Outcome Meas. 2016 Feb 3;7:13-8. doi: 10.2147/PROM.S96956. 
      eCollection 2016.